Day: November 15, 2024

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression after one or more immune checkpoint inhibitor (ICI) therapy Two PRs were observed among 3 microsatellite instability high (MSI-H) ICI resistant patients (ORR 66.7%) with both responders having pancreatic cancer including one patient with 100% tumor regression and no progression of target and non-target lesions for at least 26 months First PR observed in the combination dose escalation arm of the ABILITY-1 study in a microsatellite stable (MSS) colon cancer patient not eligible for ICI therapy, indicating MDNA11’s potential to improve outcomes for cancers that do not typically respond to ICIs Favorable safety profile in the combination dose escalation...

– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities – Company to host conference call and webcast today, November 15th, at 8:30 AM ET OCALA, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) has reported its financial results for the third quarter 2024. As previously announced, the Company will host a conference call and webcast today, November 15, 2024 at 8:30 AM ET (details below). AIM Chief Executive Officer Thomas K. Equels stated, “We are driving significant momentum across multiple clinical programs and studies that are demonstrating...

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets CAPTN-3 tri-specific antibody platform data presented at the ENA Symposium October 2024 REHOVOT, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced financial results for the three and nine months ended September 30, 2024. “Marking what we believe to be the most significant value-driving event for Purple Biotech’s clinical programs to date, we are on track to complete CM24’s...

Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments. “The third quarter was a particularly productive period for Bio-Path as we initiated our obesity program, which marks the first application of our DNAbilize® platform beyond oncology and highlights its broad therapeutic potential,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “Importantly, we continued...

Mori Arkin’s appointment as interim CEO as of January 1, 2025 approved by shareholders Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated SGT-210 proof-of-concept study in patients suffering from Darier disease is ongoingNESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update. Q3 2024 and Recent Corporate DevelopmentsOn November 4, 2024, Sol-Gel’s shareholders...

SP Group generated revenue of DKK 2,194.9 million in the 9M 2024 reporting period, a 12.4% improvement from DKK 1,953.2 million in 9M 2023. EBITDA was up by 38.1% to DKK 447.3 million from DKK 323.9 million last year, and profit before tax was up by 82.9% to DKK 254.2 million. The earnings improvement was driven by higher sales of own brands. The FY 2024 guidance provided in Announcement no. 11/2024 is narrowed. SP Group now expects FY 2024 revenue to grow by 10-16% (previously 8-18%) for an EBITDA margin of 19-21% and an EBT margin of 11-13%. See attached company announcement.AttachmentMeddelelse nr. 28 – Q3 – EN – 15 11 24

HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) — Digihost Technology Inc. (“Digihost” or the “Company”) (Nasdaq / TSXV: DGHI), an innovative energy infrastructure company that develops cutting-edge data centers, is pleased to provide a summary of the Company’s unaudited financial results for the third quarter ended September 30, 2024 (all amounts in U.S. dollars, unless otherwise indicated) and a 2024 year-to-date update on its operations. The Company’s unaudited consolidated financial statements and management’s discussion and analysis (“MD&A”) for the nine-month period ended September 30, 2024 have been filed and made accessible under the Company’s continuous disclosure profile on SEDAR+ at www.sedarplus.ca and also on EDGAR at www.sec.gov/edgar. Comparative Financial Highlights for the Three-Month Period Ended and as at September...

RIVERSIDE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) — SolarMax Technology, Inc. (Nasdaq SMXT) (“SolarMax” or the “Company”), an integrated solar energy company, today reported financial results for the quarter ended September 30, 2024. Third Quarter HighlightsRevenue: $6.3 million, compared with $14.3 million in Q3 2023. Gross profit: $1.3 million, compared with $4.0 million in Q3 2023. Total operating expense: $11.3 million, including a $7.5 million goodwill impairment relating to the China segment, compared with $3.1 million in Q3 2023. Net loss: $9.6 million, or $0.21 per share, compared with net income of $1.5 million, or $0.04 per share, in Q3 2023.David Hsu, CEO of SolarMax, stated, “Our third quarter performance reflects some of the same external factors that influenced our first half, as well as a $7.5 million goodwill...